<DOC>
	<DOCNO>NCT00590785</DOCNO>
	<brief_summary>To compare disease-free survival ( DFS ) , overall survival ( ) , toxicity high-isk primary breast cancer patient negative axillary lymph node one three positive node treat adjuvant high-dose chemotherapy doxorubicin plus cyclophosphamide ( AC ) , versus high-dose sequential chemotherapy doxorubicin follow cyclophosphamide ( A -- &gt; C ) .</brief_summary>
	<brief_title>Phase III Comparison Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin ( AC ) vs Sequential Doxorubicin Fol Cyclophosphamide ( A-C ) High Risk Breast Cancer Patients With 0-3 Positive Nodes ( Intergroup , CALGB 9394 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Patients must diagnose primary invasive adenocarcinoma breast . Those patient special type include pure tubular , mucinous papillary carcinoma eligible . Patients must sarcoma , lymphoma , apocrine , adenocystic squamous cell cancer breast . Patients must recurrent invasive breast cancer . Metaplastic carcinoma eligible variant form adenocarcinoma . Patients must undergo axillary dissection , least 6 node must een remove examined . Nodal involvement tumor must negative must xceed three positive node . disease must consider sufficiently highrisk investigator justify use chemotherapy . To eligible , disease must satisfy one follow requirement : 1 . Tumor ER negative PgR negative great 1.0 cm great diameter . Negative define c 10 fmollmg cytosol protein measure unit ; othennrise negative define accord institutional standard . 2 . Tumor great 2.0 cm great diameter irrespective hormone receptor status ( include unknown ) . 3 . Tumor involve one three axillary lymph node . Breast cancer locally advanced diagnosis . This leave investigator judgement , generally exclude patient fix tumor , fix node , peau d'orange skin change , skin ulceration inflammatory change ( T4 disease ) . Patient Is currently free breast cancer ( evidence disease ) . This also leave investigator judgement , generally include evidence distant disease chest xray mgmmogram opposite breast prior registration , within 3 month prior surgery ; gross microscopically positive surgical margin note final surgery pathology report . Patients synchronous bilateral breast cancer may consider , provide breast treat curative intent eligibility base side adverse prognostic feature . Registration must within 84 day mastectomy , within 84 day axillary dissection patient 's extensive breast surgery breast sparing procedure . Patients mastectomy breast spar surgery ineligible . Patients must prior chemotherapy breast cancer . Patients must systemic therapy type previous breast cancer . Patients must external beam radiotherapy breast cancer prior registration . Brachytherapy ( interstitial radiation therapy ) time breast sparing procedure acceptable would render patient Ineligible . ( If external beam radiotherapy plan give brachytherapy , must delay chemotherapy complete . ) Patients whose extensive breast surgery breast sparing procedure must plan receive radiotherapy chemotherapy complete . Patients must adequate hematologic , hepatic , renal cardiac function high dose chemotherapy adequate health longterm followup . This must Include normal WBC ( 2 4,0001pl ) . neutrophll count ( 2 1,50O/pl ) , platelet count ( 2 Institutional low limit normal ) , LVEF ( leave ventricular ejection fraction institutional criterion ) ; bilirubin within 1.5 time institutional upper limit normal ; creatinine within 1.5 time institutional upper limit normal ; serious disease breast cancer . Pregnant nursing woman may participate . Men ineligible . Women childbearing potential must plan use effective contraception . All patient must inform Investigational nature study give write informed consent accordance institution federal guideline . At time registration , date institutional review board approval study must provide Statistical Center .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>High Risk</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Positive Nodes</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>96-041</keyword>
</DOC>